Highlights and Quick Summary
- Consolidated Net Income/Loss for the quarter ending June 30, 2022 was $-9.01 Million (a -71.44% decrease compared to previous quarter)
- Year-over-year quarterly Consolidated Net Income/Loss increased by 31.67%
- Annual Consolidated Net Income/Loss for 2021 was $40.1 Million (a -4.17% decrease from previous year)
- Annual Consolidated Net Income/Loss for 2021 was $41.8 Million (a -380.98% decrease from previous year)
- Annual Consolidated Net Income/Loss for 2020 was $-14.9 Million (a 1.66% increase from previous year)
- Twelve month Consolidated Net Income/Loss ending June 30, 2022 was $7.77 Million (a -35.36% decrease compared to previous quarter)
- Twelve month trailing Consolidated Net Income/Loss decreased by -141.53% year-over-year
Trailing Consolidated Net Income/Loss for the last four month:
| 30 Jun '22 | 31 Mar '22 | 31 Dec '21 | 30 Sep '21 |
|---|---|---|---|
| $7.77 Million | $12 Million | $37.7 Million | $-18.7 Million |
Visit stockrow.com/BFAGY
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Consolidated Net Income/Loss of Biofrontera AG Sponsored ADR
Most recent Consolidated Net Income/Lossof BFAGY including historical data for past 10 years.Interactive Chart of Consolidated Net Income/Loss of Biofrontera AG Sponsored ADR
Biofrontera AG Sponsored ADR Consolidated Net Income/Loss for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | – | – | $-9.01 | $-31.53 | – |
| 2021 | $55.15 | $-6.84 | $-4.76 | $-5.88 | $40.06 |
| 2020 | $-1.23 | $-7.55 | $-0.08 | $-6.07 | $-14.88 |
| 2019 | – | $-5.4 | $-12.84 | $-3.0 | $-8.24 |
| 2018 | – | – | – | $-5.31 | $-10.48 |
| 2017 | – | – | $-6.91 | $-3.74 | $-18.2 |
| 2016 | $-3.85 | – | – | – | $-11.71 |
Business Profile of Biofrontera AG Sponsored ADR
Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic